<?xml version="1.0" encoding="UTF-8"?>
<ref id="B98-pharmaceuticals-14-00381">
 <label>98.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Luganini</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Mercorelli</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Messa</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Pal√π</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Gribaudo</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Loregian</surname>
    <given-names>A.</given-names>
   </name>
  </person-group>
  <article-title>The isoquinoline alkaloid berberine inhibits human cytomegalovirus replication by interfering with the viral Immediate Early-2 (IE2) protein transactivating activity</article-title>
  <source>Antivir. Res.</source>
  <year>2019</year>
  <volume>164</volume>
  <fpage>52</fpage>
  <lpage>60</lpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2019.02.006</pub-id>
  <?supplied-pmid 30738836?>
  <pub-id pub-id-type="pmid">30738836</pub-id>
 </element-citation>
</ref>
